Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The temporal and stimuli-specific effects of LPS and IFNγ on microglial activation.

Frontiers in aging neuroscience·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Fluid biomarkers for neurodegenerative diseases: a comprehensive update.

Alzheimer's research & therapy·2025
Same author

Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer's disease genetic pathways.

Molecular neurodegeneration·2025
Same author

Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.

Brain : a journal of neurology·2025
Same author

Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease.

Journal of the neurological sciences·2025

Related Experiment Video

Updated: Dec 9, 2025

Evaluation of Synapse Density in Hippocampal Rodent Brain Slices
07:44

Evaluation of Synapse Density in Hippocampal Rodent Brain Slices

Published on: October 6, 2017

17.8K

Fluid Biomarkers for Synaptic Dysfunction and Loss.

Elena Camporesi1, Johanna Nilsson1, Ann Brinkmalm1

  • 1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Biomarker Insights
|September 11, 2020
PubMed
Summary

Synapse dysfunction is key in neurodegenerative diseases like Alzheimer's. Studying cerebrospinal fluid (CSF) synaptic proteins may improve early diagnosis and monitoring of these brain disorders.

Keywords:
Alzheimer’s diseaseSynaptic biomarkerscerebrospinal fluidproteomicssynaptopathies

More Related Videos

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.9K
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K

Related Experiment Videos

Last Updated: Dec 9, 2025

Evaluation of Synapse Density in Hippocampal Rodent Brain Slices
07:44

Evaluation of Synapse Density in Hippocampal Rodent Brain Slices

Published on: October 6, 2017

17.8K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.9K
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Synaptic degeneration is an early hallmark of neurodegenerative disorders, including Alzheimer's disease (AD).
  • Synaptopathies, encompassing various neurodevelopmental and neurodegenerative conditions, share altered synaptic homeostasis as a common pathogenic event.
  • Understanding synapse dysfunction mechanisms is crucial for identifying disease-specific biomarkers and therapeutic targets.

Purpose of the Study:

  • To review pathological events leading to synapse loss.
  • To discuss established and emerging cerebrospinal fluid (CSF) biomarkers for synapse dysfunction.
  • To highlight the clinical utility, disease specificity, and detection challenges of CSF synaptic biomarkers.

Main Methods:

  • Literature review of pathological mechanisms of synapse loss.
  • Analysis of existing data on CSF synaptic proteins (e.g., neurogranin, SNAP-25, synaptotagmin-1, GAP-43, α-synuclein).
  • Evaluation of emerging CSF biomarkers such as synaptic vesicle glycoprotein 2A and neuronal pentraxins.

Main Results:

  • Synaptic protein reduction is a core feature in Alzheimer's disease pathophysiology.
  • CSF analysis offers a window into synaptic dysfunction, aiding in early diagnosis and disease monitoring.
  • Several established and novel CSF biomarkers show potential for diagnosing and tracking neurodegenerative synaptopathies.

Conclusions:

  • Synaptic pathology is central to a range of neurological disorders.
  • CSF synaptic biomarkers hold significant promise for improving the diagnosis and management of neurodegenerative diseases.
  • Further research is needed to overcome technical challenges and establish the diagnostic and prognostic value of specific CSF biomarkers.